Literature DB >> 14576137

Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.

Cécile L Tremblay1, Danielle L Poulin, Jennifer L Hicks, Subajini Selliah, Annie Chamberland, Françoise Giguel, Christopher S Kollmann, Ting Chao Chou, Huajin Dong, Martin S Hirsch.   

Abstract

We evaluated the in vitro anti-human immunodeficiency virus type 1 (HIV-1) interactions between 1-beta-D-2,6-diaminopurine dioxolane (DAPD) and enfuvirtide (T-20) against clinical isolates sensitive and resistant to reverse transcriptase and protease inhibitors. Interactions between T-20 and DAPD were synergistic to nearly additive, with combination index values ranging from 0.53 to 1.06 at 95% inhibitory concentrations. These studies suggest that a combination of T-20 and DAPD might be useful in the treatment of antiretroviral drug-experienced patients.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14576137      PMCID： PMC253786          DOI： 10.1128/AAC.47.11.3644-3646.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100.

Authors:  C L Tremblay; C Kollmann; F Giguel; T C Chou; M S Hirsch
Journal:  J Acquir Immune Defic Syndr       Date:  2000-10-01       Impact factor: 3.731

2.  Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.

Authors:  Z Gu; M A Wainberg; N Nguyen-Ba; L L'Heureux; J M de Muys; T L Bowlin; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro.

Authors:  T Mazzulli; S Rusconi; D P Merrill; R T D'Aquila; M Moonis; T C Chou; M S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  In vivo antagonism with zidovudine plus stavudine combination therapy.

Authors:  D V Havlir; C Tierney; G H Friedland; R B Pollard; L Smeaton; J P Sommadossi; L Fox; H Kessler; K H Fife; D D Richman
Journal:  J Infect Dis       Date:  2000-07-06       Impact factor: 5.226

5.  Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.

Authors:  Cécile L Tremblay; Françoise Giguel; Christopher Kollmann; Yongbiao Guan; Ting-Chao Chou; Bahige M Baroudy; Martin S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine.

Authors:  P A Furman; J Jeffrey; L L Kiefer; J Y Feng; K S Anderson; K Borroto-Esoda; E Hill; W C Copeland; C K Chu; J P Sommadossi; I Liberman; R F Schinazi; G R Painter
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Authors:  Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Donna M Jacobsen; Douglas D Richman
Journal:  Clin Infect Dis       Date:  2003-06-23       Impact factor: 9.079

8.  Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.

Authors:  D P Merrill; M Moonis; T C Chou; M S Hirsch
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

9.  1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes.

Authors:  H O Kim; R F Schinazi; S Nampalli; K Shanmuganathan; D L Cannon; A J Alves; L S Jeong; J W Beach; C K Chu
Journal:  J Med Chem       Date:  1993-01-08       Impact factor: 7.446

10.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Authors:  Jacob P Lalezari; Keith Henry; Mary O'Hearn; Julio S G Montaner; Peter J Piliero; Benôit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245
View more
  3 in total

1.  The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates.

Authors:  Nina H Lin; Daniel M Negusse; Rameen Beroukhim; Francoise Giguel; Shahin Lockman; Myron Essex; Daniel R Kuritzkes
Journal:  J Virol Methods       Date:  2010-06-25       Impact factor: 2.014

2.  TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.

Authors:  Cécile L Tremblay; Françoise Giguel; Yongbiao Guan; Ting-Chao Chou; Katsunori Takashima; Martin S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 3.  Enfuvirtide: a review of its use in the management of HIV infection.

Authors:  Vicki Oldfield; Gillian M Keating; Greg Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.